Reprogram Biosciences
PrivateLast Round
Seed
May 27, 2026
Total Funding Raised
$6M
Company Overview
Reprogram Biosciences is a biotechnology company that develops mRNA-based therapeutics that reprogram tumor cells to activate the immune system, with a focus on treating solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Reprogram Biosciences Comps
Public and private peers based on sector, stage, and business model.
Reprogram Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | May 27, 2026 |
Key People
Founding team and executive leadership
Reprogram Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| 1517 Fund | Seed |
| Unshackled Ventures | Seed |
| Narya | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 27, 2026
$6M raised from 1517 Fund, Narya, and Unshackled Ventures.
Reprogram Biosciences Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Reprogram Biosciences's valuation, stock price, and market status.
